tirzepatide and prediabetes Comparison of Clinical Efficacy Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials | Advances in Therapy 🔝🔝🔝Tirzepatide (Mounjaro/Zeppbound) does not only

Always maintain open communication with your healthcare provider about all medications, supplements, and lifestyle choices to ensure your plan is tailored safely and effectively to your individual needs

Perspective Back to Top This is extremely exciting, albeit preliminary data showing bariatric surgery-level weight loss from a medication, one that likely affords numerous other metabolic benefits, including diabetes improvement and prevention and possibly long-term cardiovascular benefit

Patients should contact their healthcare provider if they experience: Persistent vomiting lasting more than 24 hours or inability to keep down fluids, which raises concern for dehydration Signs of dehydration including decreased urination, dark urine, dizziness upon standing, extreme thirst, or dry mouth Severe abdominal pain , particularly if constant and radiating to the back, which may indicate pancreatitisa rare but serious adverse effect Hypoglycemia symptoms including sweating, tremor, palpitations, confusion, dizziness, or irritabilityespecially in patients taking concurrent insulin or sulfonylureas Right upper quadrant pain, fever, or jaundice which may indicate gallbladder disease, a reported adverse effect with tirzepatide [11] [12] Symptoms interfering with daily activities or causing significant distress despite conservative management Immediate emergency care is warranted for: Severe, unrelenting abdominal pain with vomiting Signs of acute pancreatitis (severe epigastric pain radiating to the back, fever, rapid pulse) Symptoms of severe dehydration or electrolyte imbalance (confusion, irregular heartbeat, muscle weakness) Suspected hypoglycemia with altered consciousness The FDA prescribing information specifically warns about the risk of acute kidney injury secondary to dehydration from gastrointestinal adverse effects

Other higher-risk groups include patients who are currently up-titrating, those with severe nausea or vomiting, known gastroparesis, and individuals undergoing urgent abdominal or airway procedures